Abstract
The macrocyclic lactone rapamycin has an established place as an immune suppressive agent in organ transplantation. However, more recently it has been recognized as an inhibitor of pathways that may be activated during malignant transformation and tumor progression. Thus, increasing interest is being directed to this class of antibiotic as potential antitumor agents. Here we summarize the history, mechanism of action, and mechanisms of resistance to rapamycin.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 69-78 |
| Number of pages | 10 |
| Journal | Cancer and Metastasis Reviews |
| Volume | 20 |
| Issue number | 1-2 |
| DOIs | |
| State | Published - Dec 1 2001 |
| Externally published | Yes |
Keywords
- Apoptosis
- Cancer
- Cell cycle
- Cell proliferation
- Rapamycin
- Resistance
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint Dive into the research topics of 'Resistance to rapamycin: A novel anticancer drug'. Together they form a unique fingerprint.
Cite this
Huang, S., & Houghton, P. J. (2001). Resistance to rapamycin: A novel anticancer drug. Cancer and Metastasis Reviews, 20(1-2), 69-78. https://doi.org/10.1023/A:1013167315885